Template:Desirudin: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
ShiSheng (talk | contribs)
nocaptcha
8,707 edits
No edit summary
ShiSheng (talk | contribs)
nocaptcha
8,707 edits
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
{{Desirudin}}
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Desirudin|{{fontcolor|#6C7B8B|Desirudin}}]]'''''
{{CMG}}; {{AE}}
 
'''''For patient information about Desirudin, click [[Desirudin (patient information)|here]]'''''
 
{|
|-
|-
|[[File:Desirudin01.jpg|thumb|1000px|center]]
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | IPRIVASK<sup>®</sup> FDA Package Insert
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin indications and usage|Indications and Usage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin dosage and administration|Dosage and Administration]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin contraindications|Contraindications]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin warnings and precautions|Warnings and Precautions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin use in specific populations|Use in Specific Populations]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin overdosage|Overdosage]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin description|Description]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin nonclinical toxicology|Nonclinical Toxicology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin clinical studies|Clinical Studies]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin how supplied storage and handling|How Supplied/Storage and Handling]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Desirudin labels and packages|Labels and Packages]]
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
|-
|-
|}
|}
==Overview==
Iprivask® (desirudin for injection) is a specific inhibitor of human thrombin. It has a protein structure that is similar to that of[[Hirudin]], the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. [[Hirudin]] is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. Desirudin, which is expressed in yeast (Saccharomyces cerevisiae,strain TR 1456) by recombinant DNA technology differs from the natural [[Hirudin]] by lack of a sulfate group on Tyr-63. The biological activity of desirudin is determined through a chromogenic assay which measures the ability of desirudin to inhibit the hydrolysis of a chromogenic peptidic substrate by thrombin in comparison to a desirudin standard. One vial of desirudin contains 15.75 mg desirudin corresponding to approximately 315,000 antithrombin units (ATU) or 20,000 ATU per milligram of desirudin with reference to the WHO International Standard (prepared 1991) for alphathrombin.
==Category==
Anticoagulants:Direct thrombin (II) inhibitors
==US Brand Names==
IPRIVASK
==FDA Package Insert==
'''| [[Desirudin indications and usage|Indications and Usage]]'''
'''| [[Desirudin dosage and administration|Dosage and Administration]]'''
'''| [[Desirudin dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Desirudin contraindications|Contraindications]]'''
'''| [[Desirudin warnings and precautions|Warnings and Precautions]]'''
'''| [[Desirudin adverse reactions|Adverse Reactions]]'''
'''| [[Desirudin drug interactions|Drug Interactions]]'''
'''| [[Desirudin use in specific populations|Use in Specific Populations]]'''
'''| [[Desirudin overdosage|Overdosage]]'''
'''| [[Desirudin description|Description]]'''
'''| [[Desirudin clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Desirudin nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Desirudin clinical studies|Clinical Studies]]'''
'''| [[Desirudin how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Desirudin patient counseling information|Patient Counseling Information]]'''
'''| [[Desirudin labels and packages|Labels and Packages]]'''
==Mechanism of Action==
==References==
{{Reflist|2}}
{{Antithrombotics}}
[[Category:Direct thrombin (II) inhibitors]]
[[Category:Anticoagulants]]
[[Category:Cardiovascular Drugs]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 04:13, 3 February 2014

Desirudin
IPRIVASK® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials
ClinicalTrials.gov
Retrieved from "https://www.wikidoc.org/index.php?title=Template:Desirudin&oldid=937309"